We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 26, 2021

Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer
Clin Genitourin Cancer 2021 Oct 01;19(5)447-456, D McHugh, S Tagawa, N Moryl, M Milowsky, G Heller, J Osborne, D Rathkopf, E Basch, N Pandit-Taskar, MJ Morris

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading